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Summary
Sanfilippo syndrome type B, or mucopolysaccharidosis
type IIIB, results from defects in the gene for a-N-ace-
tylglucosaminidase (NAGLU); only a few mutations
have been described. To rapidly identify most NAGLU
mutations, an automated sequencing procedure was de-
veloped for analysis of the entire coding region, includ-
ing exon-intron borders. By this method, eight affected
families were studied, and the mutations in all 16 alleles
were identified, more than doubling the number of pub-
lished mutations for this gene. Eight mutations were de-
scribed for the first time: five missense mutations
(Y140C, Y455C, P521L, S612G, and R674C), two non-
sense mutations (W675X and Q706X), and one 24-nu-
cleotide insertion. Currently, 36% of all point mutations
(8 of 22 alleles) involve R674, a codon having a CpG
dinucleotide in the critical initial position. Other mu-
tations were found in more than one family, raising the
possibility that some may be relatively common and,
possibly, ancient mutations. Six new nonpathological
mutations were also identified and likely represent poly-
morphic variants of the NAGLU gene, two of which
might alter enzyme level. Establishing genotype-pheno-
type relationships will be vital in the evaluation of ex-
perimental treatments such as gene therapy.
Introduction
The Sanfilippo syndromes are the inborn errors of gly-
cosaminoglycan metabolism that are distinguished by
the systemic accumulation of heparan sulfate and its
abnormal appearance in urine (Sanfilippo and Good
1964; Neufeld and Muenzer 1995). The lysoso-
mal hydrolase a-N-acetylglucosaminidase (NAGLU;
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E.C.3.2.1.50) is required for the removal of terminal a-
N-acetylglucosamine residues from heparan sulfate (von
Figura and Kresse 1972), and its deficiency is one of four
enzymatic defects associated with the clinical phenotype
of Sanfilippo syndrome. In patients lacking NAGLU ac-
tivity, partially degraded heparan sulfate fragments ac-
cumulate in tissues. Presumably a secondary conse-
quence, there are increased levels of gangliosides in brain
(Hara et al. 1984; Haust and Gordon 1986), a finding
that parallels the progressive cerebral atrophy of this
disorder (Murata et al. 1989).
Affected children are usually diagnosed at 2–6 years
of age, presenting with hyperactivity, attention deficit
disorder, and developmental delay. However, physical
stigmata are typically limited to hirsutism, with coars-
ening of the facial features in some cases. Neurological
deterioration progresses slowly throughout childhood,
to include the characteristic features of aphasia, vaso-
motor instability, seizures, dementia, and, eventually, a
near-vegetative state. Death ensues, typically during the
2d or 3d decade of life. Patients with a more attenuated
phenotype have been reported (Andria et al. 1979; Bal-
labio et al. 1984).
Recent isolation and characterization of the NAGLU
coding sequence and genomic DNA (Zhao et al. 1994,
1996) have been confirmed by independent partial pro-
tein sequencing and subsequent expression of a cDNA
(Weber et al. 1996). However, only a handful of mu-
tations have been identified (Zhao et al. 1996), in part
because of the difficulty encountered in sequencing the
highly GC-rich 5′ end of the gene. Despite the difficulties
in characterizing NAGLU mutations, delineating such
mutations has tremendous value, such as elucidation of
the molecular basis of variable phenotypes and facili-
tation of carrier identification, as well as selection and
evaluation of patients undergoing experimental treat-
ments such as bone-marrow transplantation and gene
therapy.
This report describes both a method for rapid se-
quencing of the entire NAGLU coding region and its
application in mutation analysis. With this approach,
the specific genetic defects in eight families have been
characterized, including one patient with the attenuated
form of Sanfilippo syndrome type B.
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Figure 1 Strategy for PCR amplification of the NAGLU gene
coding region, including the exon-intron borders. A, Sequence of
NAGLU gene, composed of six exons, which were amplified in four
PCR fragments. B, Products of PCR. Each amplicon was generated as
a unique product ready for sequencing.
Table 1
Oligonucleotide Primers for Amplification of the NAGLU Coding Region in Four Segments
AMPLICON
SIZE
(bp)
LOCATION
(Exon[s])
PRIMER
Upstream (5′ End)
(5′r3′)
Downstream (3′ End)
(5′r3′)
I 1,540 1 and 2 ACGCCCCCAAGGGAGTATC GCACGTTGAAAGCACTTCTA
II 560 3 and 4 AGCGCCCAGCACAAAGAA AAATTCCCTCTCTGAGCTAA
III 433 5 AAACCAGGAGCTGTAGAGAAGT CTGCCTACCCCTACTGACATCT
IV 1,527 6 GGCCCTCTGTTTCATCACTC CAAGCGTGGCAGCAGTGACC
Patients and Methods
Patients
Subjects were patients of the University of Minnesota
whose diagnosis was established on the basis of defi-
ciency of plasma NAGLU enzyme, pathological eleva-
tion of heparan sulfate in urine, and the presence of
characteristic clinical features.
Molecular-Genetic Methods for Automated Analysis
Extensive work was done to develop a series of oli-
gonucleotide primers and reaction conditions that would
yield amplicons and would allow for their sequencing
under a uniform set of conditions that have been de-
scribed, in part, elsewhere (Aronovich et al. 1996) and
that are detailed below. Oligonucleotide primers used
for PCR amplification and sequencing in this study were
synthesized on an Applied Biosystems 391 DNA
Synthesizer.
Amplification of NAGLU Genomic DNA
Genomic DNA was isolated, by use of a Puregene
DNA isolation kit (Gentra Systems), either from 3 ml
whole blood, from 0.5–2# 106 lymphoblastoid cell line
(LCL) cells, or from a flask (T-125; Falcon) of cultured
fibroblasts. Four PCR reactions were developed to am-
plify the six exons of the NAGLU gene, including exon-
intron junctions (fig. 1). Each PCR was performed on a
thermocycler (GeneAmp PCR System 9600; Perkin-El-
mer), in a total volume of 50 ml containing 0.6–1 mg
genomic DNA, 25 pmol each of a pair of primers (table
1), 800 mM each dNTP, 60 mM Tris-HCl (pH 9.0 at
22C), 15 mM (NH4)2SO4, 1.5 mMMgCl2, and 2.5 units
thermostable DNA polymerase (Taq polymerase; Boeh-
ringer Mannheim). For the amplicon extending over ex-
ons 1 and 2, the amplification reaction was supple-
mented to include 10% dimethyl sulfoxide. After
denaturation (95C for 1 min), each of the four separate
PCR fragments was generated by 40 cycles of a program
comprising denaturation (95C for 30 s), annealing
(55C for 30 s), and extension (72C for 30 s). Each of
the four PCR products was isolated by use of aQIAquick
PCR purification kit (QIAGEN), and an aliquot (3 ml)
was evaluated, for concentration and size, by electro-
phoresis (0.8% agarose gel stained with ethidium bro-
mide), by comparison with a molecular marker (500-bp
ladder; Invitrogen).
Sequencing Technique
Automated sequencing was done by cycle sequencing
in reactions containing 100 ng DNA template, 3.2 pmol
appropriate primer (table 2), and fluorescent dideoxy-
nucleotides (PRISM Ready Reaction Dye Deoxy Ter-
minator cycle sequencing kit; Applied Biosystems). After
initial denaturation (96C for 1 min), cycle sequencing
reactions were performed with 30 cycles of a program
comprising denaturation (96C for 10 s), annealing
(50C for 5 s), and elongation (60C for 4 min). Products
of sequencing reactions were isolated by gel-filtration
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Table 2
Oligonucleotide Primers for Automated Sequencing of the NAGLU
Coding Region
Primer
Oligonucleotide Sequence
(5′r3′) DNA Strand Location
1 ACGCCCCCAAGGGAGTAT Sense 1
2 GTACCCGGAAGCCGCGACTC Sense 1
3 GCGGCGGTGGGGGTCCTTCT Sense 1
4 AAGGCAGAGTGGCTGGCTCAA Antisense 1
5 GCCCAGGCTGTAGGTGTC Antisense 1
6 CAGAAGGGCCGAGTTTGGAG Sense 2
7 GCACGTTGAAAGCACTTCTA Antisense 2
8 AGCACAAAGAAGCAATGAGT Sense 3
9 GTGTACCTGGCCTTGGGCCT Sense 3
10 CCTCATCTCCCAGGATACACG Antisense 3
11 AAATTCCCTCTCTGAGCTAA Antisense 4
12 CATCTGCTACTCCCTTCTTT Antisense 5
13 GCTGTTGAACACTATGGTGA Sense 5
14 CCAAGGCTGGCTCTTCCAGCA Sense 6
15 TCACAGCCTCTAGGGCTCCAA Antisense 6
16 CACCATGGTAGGCACGGGCAT Sense 6
17 TCCTCCGTTCTTCGCGGATGG Antisense 6
18 TAGCCTCCACGCTGCCCCT Antisense 6
19 CAACCGATCTGATGTGTTTG Sense 6
20 TTGGCATAGTCCAGGATGTTG Antisense 6
21 GGTTGGTGGCCAACTACTACA Sense 6
22 TGTGATGTCTGTCCAGCTCT Antisense 6
Figure 2 Distribution of 22 sequencing reactions extending over the entire NAGLU coding region. AB373 sequence “base calls” and
electrophoretofluorograms are transferred to a free-standing program (Sequencher 3.0), for alignment and analysis. With this strategy, the entire
coding region, including exon-intron borders, is sequenced, in both the 5′r3′ direction and the 3′r5′ direction.
chromatography (CENTRI-SEP column; Princeton Sep-
arations) and were loaded on a 6% denaturing poly-
acrylamide gel for electrophoresis on an automated se-
quenator instrument (model 373A; Applied Biosystems).
Electronic sequence data were transferred to alignment
software (Sequencher 3.0; Gene Codes Corporation)
running on a desktop computer (Power Macintosh
model 7600; Apple).
Nomenclature
Mutations are reported in terms of standard nomen-
clature as recently recommended by consensus groups
(Beaudet and Tsui 1993; Beutler et al. 1996). Positions
in the DNA and amino acid sequences are enumerated
from the first nucleotide of the initial ATG codon (i.e.,
cDNA designation). However, intronic nucleotides are
designated with respect to the genomic sequence
(GenBank accession number U43572) and are prefixed
with a “g.” Mutations have been submitted to the MPS
Mutation Database (http://www.peds.umn.edu/Centers/
gene/).
Results
Identification of NAGLU Mutations
Prior experience had demonstrated that the GC-rich
5′ end of the gene was extremely difficult to amplify and
sequence. Extensive work was done to identify primers
and reaction conditions for a reliable and reproducible
method, part of which has been outlined in a preliminary
report (Aronovich et al. 1996) and is detailed here. Four
DNA segments were amplified from genomic template
in a manner that included exon-intron borders (fig. 1).
These amplicons were then analyzed in a series of 22
overlapping dye-terminator cycle sequencing reactions
that evaluated each of 4,060 nucleotide positions, each
read in both the 5′r3′ direction and the 3′r5′ direction
(fig. 2). Sequencing calls and electrophoretofluorogram
tracings from an AB373 Sequenator were transferred to
a Macintosh computer and were compared, with the
assistance of Sequencher 3.0 software, with the patterns
of normal DNA. Eight unrelated families were studied,
among which eight novel mutations and six other, un-
reported DNA variations were identified (table 3).
Family A: Y140C (419ArG) and R674C (2020CrT)
Two mutations were identified in a 24-year-old female
with end-stage Sanfilippo syndrome (fig. 3). This neu-
rologically devastated woman used no expressive lan-
Table 3
Summary of Pathological NAGLU Mutations and Clinical Phenotype in Patients with Sanfilippo Syndrome Type B
Family Allele 1 Mutation (Enzyme Alteration) Allele 2 Mutation (Enzyme Alteration) Phenotype Current Clinical Status
A 419ArG (Y140C) 2020CrT (R674C) Severe Living 24-year-old female with end-stage neuro-
logical debilitation
B 503delGGAGCGGCCA (truncated protein) 503delGGAGCGGCCA (truncated protein) Severe Proband deceased at age 16¼ years
Severe Second affected sibling deceased at age 16⅔
years
C 889CrT (R297X) 889CrT (R297X) Severe Living, severely demented at age 13 years, de-
spite marrow transplantation
D 1364ArG (Y455C) 2021ArG (R674H) Living 6-year-old with near-normal
development
E 1364ArG (Y455C) 1562CrT (P521L) Severe Proband a 28-year-old neurologically devastated
female
Severe Second affected sibling a 25-year-old neurologi-
cally devastated male
Severe Third affected sibling a 23-year-old neurologi-
cally devastated male
F 2020CrT (R674C) 2021GrA (R674H) Severe Living 6-year-old female with moderate mental
retardation
G 2024GrA (W675X) 2116CrT (Q706X) Severe Living 6-year-old female with moderate mental
retardation
H 1834ArG (S612G) 233insGCGGCGCGGCGCGCGTGCGGGTGC Attenuated Physically active 32-year-old female with mod-
erate mental retardation
Normal variant 423CrT (S141S) 933CrG (A311A) ) Child exhibiting reduced NAGLU catalytic ac-
tivity with normal glycosaminoglycan
excretion
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Figure 3 Representative electrophoretofluorographs of an af-
fected individual and probands from families A, D, and F, illustrating
the normal and mutant patterns at the R674 hot spot. Arrows indicate
mutant nucleotides.
guage and had a spastic neuromuscular examination.
During a prolonged period of illness, she had required
a gastrostomy tube, which was removed after several
months; however, she eats a bulbar diet, which is spoon
fed. The proband was found to be heterozygous for two
novel mutations, Y140C (419ArG) and R674C
(2020CrT). In addition, the proband was found to be
heterozygous for a previously unreported silent muta-
tion, 1828CrT (L610L).
Family B: 10-nt Deletion
In an Italian-American family with two deceased, af-
fected children, mutations were sought by analysis of
both parents and an unaffected sibling. All three indi-
viduals were found to be heterozygous for a 10-nt de-
letion, 503delGGAGCGGCCA. Homozygosity for this
same mutation was previously reported in an indepen-
dently ascertained proband from Italy (Zhao et al.
1996), thus suggesting the possibility of a common, Ital-
ian source.
Family C: R297X (889CrT)
The proband in this family was the first patient in
North America to undergo allogeneic bone marrow
transplantation for Sanfilippo syndrome type B. As a
newborn, the infant had an extremely complicated clin-
ical course. An atonic stomach and related feeding prob-
lems required 11 surgical procedures during infancy and
led to early recognition of mucopolysaccharidosis (MPS)
IIIB, the diagnosis based on unexpected lysosomal in-
clusions identified in a stomach biopsy. At 20 mo of age,
the patient underwent allogeneic bone-marrow trans-
plantation (at the University of Minnesota on November
14, 1986), receiving marrow from his HLA-identical
brother. The proband achieved full donor engraftment
(199% donor), as determined by DNA markers. After
the transplantation, normal homozygote donor levels of
leukocyte NAGLU enzyme activity were achieved (fig.
4A). There was a corresponding decrease in urinary gly-
cosaminoglycan excretion (fig. 4B and C), although lev-
els never reached the normal range. Now, at 13 years
of age, the patient is ambulatory, with minimal physical
disabilities, but has persistent mixed conductive and sen-
sorineural hearing loss. He remains severely retarded
(fig. 4D) and has never acquired meaningful expressive
language.
From frozen LCL cells stored prior to transplantation,
the mutation R297X was observed as the only deviation
from the consensus sequence. Although the parents were
unaware of any consanguinity, the patient was found to
be homozygous throughout the NAGLU coding region.
Family D: Y455C (1364ArG) and R674H (2021GrA)
In a 6-year-old female with essentially normal devel-
opment, two mutations were identified. The proband
was heterozygous for mutation 1364ArG in exon 6,
which causes the normal tyrosine to be replaced by cys-
teine at amino acid 455. This change occurs in a region
that is highly conserved in both the human and bovine
NAGLU proteins, there being 87.9% identity in a 33-
peptide segment centered relative to this position (H. G.
Zhao and E. F. Neufeld, unpublished observation). The
patient (fig. 3) was also found to be heterozygous for
2021GrA (R674H), a previously reported mutation
(Zhao et al. 1996).
Family E: P521L (1562CrT) and Y455C (1364ArG)
In a sibship of two affected males and one affected
female with severe disease, the proband was found to
be heterozygous for two missense mutations. One mu-
tation, 1364ArG (Y455C), was observed in an unre-
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Figure 4 Clinical features of the proband with Sanfilippo syn-
drome type B, in family C, who underwent bone-marrow transplan-
tation (•). The features compared are leukocyte NAGLU enzyme ac-
tivity (A), urine glycosaminoglycan levels (mg uronic acid/g creatinine
[B] or mg uronic acid/g creatinine/24 h [C]), and intelligence quotient
from representative tests or subtests—i.e., either MDI of Bayley Scales
or Stanford-Binet Intelligence Scale, 4th ed., composite score (D) .
Results are plotted against the normal range (gray shading) and are
compared with values for untreated patients with Sanfilippo syndrome
types A (), B (), and C ().
lated family (family D, discussed above), and the second
was a unique mutation, 1562CrT (P521L). In addition,
this patient was found to be homozygous for two in-
tronic 1-nt changes, one being a deletion (g2093delA)
and the other being an insertion (g2308insA).
Complete analysis of the proband’ s unaffected sister
demonstrated that she had neither of her sibling’s path-
ological mutations but was homozygous for g2308insA
and was also homozygous for another intron mutation,
g2744GrC.
Family F: R674C (2020CrT) and R674H (2021GrA)
A 6-year-old girl with moderate mental retardation
and typical physical features was found to be hetero-
zygous for two different mutations affecting codon 674
(fig. 3). The patient had the mutation 2020CrT
(R674C) seen in the proband of family A (discussed
above) and also had 2021GrA (R674H), which previ-
ously had been observed in two Arabian patients (Zhao
et al. 1996). These mutations were also found in the
patient’s parents, the former being found in the mother
and the latter being present in the father.
Family G: W675X (2024GrA) and Q706X (2116CrT)
In a 6-½-year-old female with moderate mental re-
tardation and typical physical features, two nonsense
mutations were identified. The proband was heterozy-
gous for 2024GrA (W675X ) and also was heterozy-
gous for 2116CrT (Q706X).
Family H: Attenuated Sanfilippo Syndrome Type B,
S612G (1834ArG), and a 24-nt Insertion
Mutations were studied in a unique patient with the
attenuated form of Sanfilippo syndrome type B. At age
32 years, the proband was somewhat retarded, as illus-
trated by her ability to be employed in a sheltered work-
shop where, on a typical day, she assembled 1,000 card-
board boxes during an 8-h work shift. The proband and
her father both were found to have overlapping peaks
of guanine and adenine at nucleotide 1834—that is,
1834ArG (S612G). The mother showed the normal se-
quence, except for a 24-nt in-frame insertion—
233insGCGGCGCGGCGCGCGTGCGGGTGC—also
found in the proband.
Nonpathological, Reduced NAGLU Activity
A patient of Israeli ethnogeographic background pre-
viously had been found to have low NAGLU enzyme
activity in the heterozygote range, as measured in plasma
and cultured fibroblasts. Mutation analysis demon-
strated an entirely normal sequence, except that the pa-
tient was heterozygous for two, previously unreported
silent mutations—423CrT (S141S) and 933CrG
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Figure 5 Mutation map of the NAGLU gene. Exons 1–6 are represented by unblackened boxes. The position and clinical effect of the
mutations are shown above the gene:   missense mutation; • nonsense mutation;   silent mutation (presumed polymorphism); D 
insertion; and   deletion.
(A311A)—neither of which has been observed in any
previous studies. Although these changes would not be
expected to have any effect on protein structure, it is
possible that one or both could result in reduced trans-
lational efficiency because of the use of low-frequency
codons. Such changes are known to have significant ef-
fects on the biology of other organisms and recently have
been demonstrated to be the molecular basis of the Los
Angeles biochemical phenotype of galactosemia (Lang-
ley et al. 1997).
Discussion
The primary clinical impetus to mutation analysis for
Sanfilippo syndrome type B has been to provide more-
accurate and specific carrier testing for the relatives of
an affected individual. In the past, identification of car-
riers among relatives has been attempted by quantitative
enzyme assays (von Figura et al. 1973, 1975). However,
this method is subject to error, because of the variability
intrinsic to enzyme-assay methods, differences in poly-
morphic variants with altered catalytic activity, as well
as other potential biological variations (Vance et al.
1980, 1981; Pande et al. 1992).
The automated sequencing method developed here
provides a satisfactory method to identify virtually all
mutations of the NAGLU gene. Oligonucleotide primers
and reaction conditions developed for this study have
resolved the difficulties in analysis of the GC-rich 5′ end
of the NAGLU gene. To achieve this level of confidence
and accuracy, the analytic method was extended beyond
the simple acceptance of “base calls” assigned by the
sequenator computer; better evaluations were achieved
by down-loading electrophoretofluorogram tracings into
supplementary alignment and analysis software (i.e., Se-
quencher), for visual comparison of “test” and “nor-
mal” profiles. Analysis is further aided by comparison
of multiple sequencing reactions that cover cycle-se-
quencing reactions reading both the 5′r3′ and 3′r5′ di-
rections of the gene. This bidirectional analysis essen-
tially doubles the number of sequencing reactions
required but greatly aides in resolving ambiguities. This
redundancy also serves to provide an internal validation
of the method.
In this series of patients the method of sequence anal-
ysis appears to readily identify concurrent heterozygous
mutations. This was demonstrated in cases of known
point mutations and known deletions and also was the
means by which several previously unknown mutations
and polymorphisms were identified. Ongoing experience
should further assess the sensitivity of this seemingly
reliable system.
Mutation analysis is important for other reasons, not
the least of which are to gain insights into the molecular
pathology of this disease and to establish genotype-phe-
notype relationships. (Note that the phrase “genotype-
phenotype correlation” has been used to describe the
association between particular genotypes and specific
clinical phenotypes. Despite the fact that statistical anal-
ysis would be particularly valuable, there is rarely any
attempt to establish the statistical basis for such asso-
ciations—e.g., with a “correlation coefficient.” To en-
courage the statistical approach, we reserve the termi-
nology “genotype-phenotype correlation” for those
associations in which statistical analysis has been ac-
complished. When an important genotype-phenotype
association is suggested but is not statistically
evaluated, we describe this as a “relationship” or
“correspondence.”)
Rare patients with a more attenuated phenotype of
Sanfilippo syndrome have been reported (Andria et al.
1979; van de Kamp et al. 1981; Di Natale et al. 1982;
von Figura et al. 1984; van Schrojenstein-de Valk and
van de Kamp 1987; Di Natale 1991). Historically, such
patients, with a more slowly progressive form of the
disease, have been described as representing the “mild
form” of Sanfilippo syndrome (or some other MPS dis-
order). However, the neurologically devastating clinical
course is not “mild” in any sense of the word, and this
term only serves to mislead clinicians and relatives about
the horrendous neurological deterioration of such in-
dividuals. We have therefore abandoned this misleading
Table 4
Mutations of the NAGLU Gene
Number Exon Genotype CpGa
No. of Independent
Observations of
Allelesb
Biochemical Phenotype
(NAGLU Protein) Clinical Phenotype Reference
1 1 233insGCGGCGCGGCGCGCGTGCGGGTGC 2 8-Amino-acid insertion Sanfilippo syndromec Present report
2 Intron 1 g2089delA 2 Normal Polymorphismd Present report
3 Intron 1 g2304insA 2 Normal Polymorphismd Present report
4 2 419ArG 1 Y140C Sanfilippo syndrome Present report
5 2 423CrT 1 S141Se Polymorphismd Present report
6 2 503delGGAGCGGCCA 5 Truncated at 182 Sanfilippo syndrome Zhao et al. (1996)
7 Intron 2 g2739GrC 20 Normal Polymorphismd Present report
8 5 889CrT  3 R297X Sanfilippo syndrome Zhao et al. (1996)
9 5 933CrG 1 A311Ae Polymorphismd Present report
10 6 1364ArG 2 Y455C Sanfilippo syndrome Present report
11 6 1562CrT  1 P521L Sanfilippo syndrome Present report
12 6 1828CrT 2 L610L Polymorphismd Present report
13 6 1834ArG 2 S612G Sanfilippo syndromec Present report
14 6 1876CrT  2 R626X Sanfilippo syndrome Zhao et al. (1996)
15 6 1928GrA  1 R643H Sanfilippo syndrome Zhao et al. (1996)
16 6 2020CrT  3 R674C Sanfilippo syndrome Present report
17 6 2021GrA  7 R674H Sanfilippo syndrome Zhao et al. (1996)
18 6 2024GrA 1 W675X Sanfilippo syndrome Present report
19 6 2116CrT 1 Q706X Sanfilippo syndrome Present report
Other, normal alleles 9
a A plus sign () denotes presence of CpG.
b A total of 36 alleles were studied.
c Associated with the attenuated phenotype of Sanfilippo syndrome in a single compound-heterozygote individual. Additional cases are required in order to establish the
clinical phenotype associated with the allele.
d Normal variant allele, which is presumed to be a polymorphism, although the numbers of observations are currently insufficient to meet the formal definition.
e Possibly associated with reduced NAGLU catalytic activity; however, additional cases are required in order to confirm this association.
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terminology, in favor of a more accurate designa-
tion—referring to forms with more slowly evolving dis-
ease as the “attenuated form.”
In cell-fusion studies using fibroblasts from a patient
with the attenuated form (Andria et al. 1979) and cells
from more typically severe cases, no complementation
was observed in heterokaryons, thus indicating that
these forms might be ascribed to allelic mutations (Bal-
labio et al. 1984). In fact, the molecular biology of sev-
eral lysosomal storage disorders suggests that some mu-
tations result in “residual enzyme activity” responsible
for the attenuated phenotype. The present report in-
cludes another case (family H) and confirms that such
a patient with attenuated disease does have two allelic
mutations. Although there are no biological markers or
assays for this phenotype (e.g., residual enzyme activity
or glycosaminoglycan levels), a catalog of specific mu-
tations may provide a means for early identification of
such individuals.
In the course of the present study of several affected
individuals, a series of eight patients revealed eight pre-
viously unreported mutations. Five missense mutations
(Y140C, Y455C, P521L, S612G, and R674C), two non-
sense mutations (W675X and Q706X), and one 24-nt
insertion (233insGCGGCGCGGCGCGCGTGCGGT-
GC) have been characterized. In addition, this study has
identified six new polymorphisms: g2089delA,
g2304insA, 423CrT (S141S), g2739GrC, 933CrG
(A311A), and 1828CrT (L610L). Point mutations, de-
letions, insertions, and polymorphisms have been re-
ported in the NAGLU gene (fig. 5) and are summarized
in table 4.
To date, ∼36% of all point mutations (8 of 22 alleles)
involve a substitution for arginine at the CGC codon
674. Although the number of subjects is limited to 13
published individuals, this locus appears to be a “hot
spot” for 1-bp substitution. Two of the nine most likely
1-nt substitutions at this codon have been observed, both
occurring at the CpG dinucleotide: the CrT transition
at nucleotide 2020 (CGCrTGC), causing R674C, and
the GrA transition at nucleotide 2021 (CGCrCAC),
resulting in R674H. Except for this codon, the majority
of the currently known pathological mutations in the
NAGLU gene are heterogeneous, typically unique to the
affected family and usually not found in unrelated
patients.
Concomitantly with this study of pathological mu-
tations, six apparently silent mutations were identified
(table 4). Of the six variants, each occurred in a single
family, except for g2739GrC, which previously had
been reported in an unrelated individual (Zhao et al.
1996). Although these mutations are not likely to have
any effect on molecular or clinical phenotype, the lack
of population studies constrains formal recognition of
these changes as “polymorphisms.” Two of these mu-
tations, 423CrT (S141S) and 933CrG (A311A), oc-
curred in an individual who had half-normal levels of
NAGLU enzyme in plasma and cultured fibroblasts.
Such mutations might subject NAGLU mRNA to un-
favorable codon utilization and thus reduce the level of
enzyme that is synthesized, resulting in a reduced-activity
variant. Such biased codon utilization may have broad
significance in evolution (Powell and Moriyama 1997)
and recently has been proposed as the molecular basis
of the Los Angeles biochemical phenotype of galacto-
semia (Langley et al. 1997). These two NAGLU muta-
tions are probably not pathological, insofar as this in-
dividual was found to have normal glycosaminoglycan
excretion.
For some patients with MPS diseases, such as Hurler
syndrome (MPS type I), very early bone marrow trans-
plantation can result in a “normal” long-term intellec-
tual outcome even in children with “severe” mutations
(Whitley et al. 1993a, 1993b). However, the outcome
for children with Sanfilippo syndrome has been less well
defined. An earlier report of transplantation in two chil-
dren with Sanfilippo syndrome type B was equivocal,
indicating that neither was as handicapped as an un-
treated sibling of the same age, although hyperactivity
and behavioral problems were present in one of them
(Vellodi et al. 1992). In contrast, the outcome for a pa-
tient (in family B) in the present study was clearly poor;
although the patient achieved donor levels of leukocyte
enzyme and reduced glycosaminoglycan excretion, urine
heparan sulfate did not reach the normal range, nor was
the intellectual outcome good. The establishment of ge-
notype-phenotype relationships would markedly im-
prove the interpretation of such clinical trials, perhaps
offering insight into the variations. For example, there
is growing concern that the immunogenicity of foreign,
albeit therapeutic, proteins may be a limiting factor in
cellular therapies. Recent gene-marking studies have ob-
served adverse infusion reactions (Selvaggi et al. 1997),
which may be due to introduction of a bovine antigen
during cell culture (Muul et al. 1997). In a clinical trial
of gene therapy, inclusion of the bacterial neomycin-
resistance gene in retroviral vectors has sensitized pa-
tients, resulting in T–lymphocyte-mediated elimination
of cells (Muul et al. 1997), thereby reducing therapeutic
efficacy. Introduction of the normal protein into a pa-
tient with a mutant enzyme has the potential to result
in similar problems. For example, 13% of patients with
Gaucher disease who receive b-glucocerebrosidase de-
velop antibodies against the normal enzyme (Richards
et al. 1993), rarely causing anaphylaxis. For this reason,
it may be important to know the precise mutations of
each patient receiving such therapies, to identify which
mutations are likely to be associated with immune elim-
ination/inactivation and other adverse effects.
On the basis of the present and previous studies, there
62 Am. J. Hum. Genet. 62:53–63, 1998
is an emerging view of the normal NAGLU gene and its
variants. Several mutations are recurrent at the “hot
spot” R674. However, most others have been observed
in at least two unrelated individuals and likely reflect
ancient mutational events. Further work is needed in
diverse ethnogeographic populations; however, it is be-
coming clear that the vast majority of mutations result
in a relatively severe phenotype, with early and pro-
gressive mental retardation. Only one individual with a
relatively attenuated phenotype has been studied. How-
ever, even this patient is reported to have had progression
of intellectual impairment at age 32 years. In this case,
two mutations merit further study, and we speculate that
at least one of them results in some small level of residual
enzyme activity, thus accounting for the attenuated phe-
notype. Such information may be helpful, both in the
provision of prognostic information for newly diagnosed
patients and in the evaluation of therapies.
Acknowledgments
We thank Dr. Eric Eccleston (Institute of Human Genetics,
University of Minnesota) for operation of the Sequenator. This
work was supported by the Children’sMedical Research Foun-
dation (Susan and Brad Wilson, cofounders) (Chicago).
References
Andria G, Di Natale P, Del Giudice E, Strisciuglio P, Murino
P (1979) Sanfilippo B syndrome (MPS III B): mild and
severe forms within the same sibship. Clin Genet 15:
500–504
Aronovich EL, Zhao HG, Neufeld EF, Whitley CB (1996)
Mutation analysis in Sanfilippo syndrome type B by au-
tomated sequencing of the NAGLU coding region. Am J
Hum Genet Suppl 59:A246
Ballabio A, Pallini R, Di NP (1984) Mucopolysaccharidosis
III B: hybridization studies on fibroblasts from a mild
case and fibroblasts from severe patients. Clin Genet 25:
191–195
Beaudet AL, Tsui LC (1993) A suggested nomenclature for
designating mutations. Hum Mutat 2:245–248
Beutler E, McKusick VA, Motulsky AG, Scriver CR, Hutch-
inson F (1996) Mutation nomenclature: nicknames, sys-
tematic names, and unique identifiers. Hum Mutat 8:
203–206
Di Natale P (1991) Sanfilippo B disease: a re-examination
of a particular sibship after 12 years. J Inherit Metab Dis
14:23–28
Di Natale P, Murino P, Pontarelli G, Salvatore D, Andria
G (1982) Sanfilippo B syndrome (MPS III B): altered re-
sidual alpha-N-acetylglucosaminidase activity in an un-
usual sibship. Clin Chim Acta 122:135–143
Hara A, Kitazawa N, Taketomi T (1984) Abnormalities of
glycosphingolipids in mucopolysaccharidosis type III B.
J Lipid Res 25:175–184
Haust MD, Gordon BA (1986) Ultrastructural and bio-
chemical aspects of the Sanfilippo syndrome—type III ge-
netic mucopolysaccharidosis. Connect Tissue Res 15:
57–64
Langley SD, Lai K, Dembure PP, Hjelm LN, Elsas LJ (1997)
Molecular basis for Duarte and Los Angeles variant ga-
lactosemia. Am J Hum Genet 60:366–372
Murata R, Nakajima S, Tanaka A, Miyagi N, Matsuoka O,
Kogame S, Inoue Y (1989) MR imaging of the brain in
patients with mucopolysaccharidosis. Am J Neuroradiol
10:1165–1170
Muul LM, Soenen SL, Walker R, Ram Z, Oldfield EH,
Blaese RM (1997) Studies of the immune response in pa-
tients receiving gene therapy. In: Blau HM, Wilson JM
(eds) Molecular and cellular biology of gene therapy. Key-
stone Symposia, Snowbird, UT, pp 52
Neufeld EF, Muenzer J (1995) The mucopolysaccharidoses.
In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The
metabolic and molecular basis of inherited disease, 7th
ed. McGraw-Hill, New York, pp 2465–2494
Pande H, Chester A, Lie H, Thorsby E, Stormorken H
(1992) Concomitant occurrence of mucopolysacchari-
dosis IIIB and Glanzmann’s thrombasthenia: further ev-
idence of a hyperactive alpha-N-acetylglucosaminidase-
producing allele. Clin Genet 41:243–247
Powell JR, Moriyama EN (1997) Evolution of codon usage
bias in Drosophila. Proc Natl Acad Sci USA 94:
7784–7790
Richards SM, Olson TA, McPherson JM (1993) Antibody
response in patients with Gaucher disease after repeated
infusion with macrophage-targeted glucocerebrosidase.
Blood 82:1402–1409
Sanfilippo SJ, Good RA (1964) A laboratory study of the
Hurler syndrome. Am J Dis Child 102:140
Selvaggi TA, Walker RE, Fleisher TA (1997) Development
of antibodies to fetal calf serum with arthus-like reactions
in human immunodeficiency virus-infected patients given
syngeneic lymphocyte infusions. Blood 89:776–779
Vance JM, Conneally PM, Wappner RS, Yu PL, Brandt IK,
Pericak-Vance MA (1981) Carrier detection in Sanfilippo
syndrome type B: report of six families. Clin Genet 20:
135–140
Vance JM, Pericak-Vance MA, Elston RC, Conneally PM,
Namboodiri KK, Wappner RS, Yu PL (1980) Evidence of
genetic variation for alpha-N-acetyl-D-glucosaminidase
in black and white populations: a new polymorphism.
Am J Med Genet 7:131–140
van de Kamp J, Niermeijer MF, von Figura K, Giesberts
MA (1981) Genetic heterogeneity and clinical variability
in the Sanfilippo syndrome (types A, B, and C). Clin Ge-
net 20:152–160
van Schrojenstein-de Valk H, van de Kamp J (1987) Follow-
up on seven adult patients with mild Sanfilippo B-disease.
Am J Med Genet 28:125–129
Vellodi A, Young E, New M, Pot-Mees C, Hugh-Jones K
(1992) Bone marrow transplantation for Sanfilippo dis-
ease type B. J Inherit Metab Dis 15:911–918
von Figura K, Hasilik A, Steckel F, van de Kamp J (1984)
Biosynthesis and maturation of a-N-acetylglucosamini-
dase in normal and Sanfilippo B-fibroblasts. Am J Hum
Genet 36:93–100
von Figura K, Kresse H (1972) The Sanfilippo B corrective
Zhao et al.: Sanfilippo Syndrome Type B 63
factor: a N-acetyl-alpha-D-glucosamindiase. Biochem
Biophys Res Commun 48:262–269
von Figura K, Logering M, Kresse H (1975) Serum alpha-
N-acetylglucosaminidase: determination, characteriza-
tion, and corrective activity in Sanifilippo B fibroblasts.
Z Klin Chem Klin Biochem 13:285–289
von Figura K, Logering M, Mersmann G, Kresse H (1973)
Sanfilippo B disease: serum assays for detection of ho-
mozygous and heterozygous individuals in three families.
J Pediatr 83:607–611
Weber B, Blanch L, Clements PR, Scott HS, Hopwood JJ
(1996) Cloning and expression of the gene involved in
Sanfilippo B syndrome (mucopolysaccharidosis III B).
Hum Mol Genet 5:771–777
Whitley CB, Belani KG, Chang PN, Summers CG, Blazar
BR, Tsai MY, Latchaw RE, et al (1993) Long-term out-
come of Hurler syndrome following bone marrow trans-
plantation. Am J Med Genet 46:209–218
Whitley CB, Krivit W, Ramsay NKC, Kersey JH, Chang PN,
Latchaw RE, Blazar BR, et al (1993) Mutation analysis
and clinical outcome of patients with Hurler syndrome
(mucopolysaccharidosis type I-H) undergoing bone mar-
row transplantation. Am J Hum Genet Suppl 53:101
Zhao HG, Li HH, Bach G, Schmidtchen A, Neufeld EF
(1996) The molecular basis of Sanfilippo syndrome type
B. Proc Natl Acad Sci USA 93:6101–6105
Zhao HG, Lopez R, Rennecker J, Neufeld EF (1994) San-
filippo syndrome type B: cDNA and gene encoding human
a-N-acetyl glycosaminidase. Am J Hum Genet Suppl 55:
A252
